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thrombus aspiration may prevent four deaths per thousand at the cost
of two strokes per thousand. Although this may initially sound
favorable for the procedure, the conﬁdence interval for mortality is
still wide enough to encompass no effect, while that of stroke is not.
With mortality now so low in STEMI trials, very large numbers of
patients are required to reliably identify a clinically important
improvement. The task requires massive multi-center trials or stra-
tegies that minimize per-patient costs by using established outcome-
reporting infrastructure to focus on mortality, and perhaps introduce
“retrospective consent”.
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BACKGROUND Several studies of acute myocardial infarction (MI)
have documented the prognostic importance of early post-MI infarct
size related to long-term outcomes such as mortality or heart failure
(HF). However, whether a change in infarct size due to an inter-
vention is related to the intervention’s effect on outcomes has not
been conclusively demonstrated. We used patient-level data from
acute MI primary PCI trials to assess the relation between short-term
effects on infarct size and longer-term effects on outcomes. We hy-
pothesized that a therapy-induced change in infarct size would be
related in direction and/or magnitude to the outcome effect of that
therapy.
METHODS We combined patient-level data from 10 randomized
clinical trials that tested various therapies for ST elevation MI
(STEMI). Infarct size was assessed by sestamibi imaging in 3 trials and
by cardiac magnetic resonance imaging in 7 trials, using standard
techniques with analysis in core labs, and was expressed as a % of left
ventricular (LV) mass. Each patient within a trial was assigned a
variable to represent that study treatment’s mean effect on infarct
size based on whether the patient was in the treatment or placebo
group. Cox proportional hazards models estimated the association of
treatment-related infarct size to one-year adjudicated clinical out-
comes of hospitalization for heart failure and all-cause mortality.
RESULTS The 10 trials included 2,458 patients, 24% women, 7% with
prior MI. Infarct size was measured at a median of 5 days post-MI.
Mean trial infarct size in the control groups in the 10 trials ranged from
12% - 35% of the LV, and from 12% - 40% among treatment groups.
There was a signiﬁcant relation of treatment effect on infarct size to
treatment effect on one-year HF hospitalization (HR 0.83, 95% CI 0.75
to 0.93, p<0.001). There was no signiﬁcant relation between treat-
ment effect on infarct size to treatment effect on one-year mortality
(HR 1.04, 95% CI 0.94 to 1.15). The relation to HF hospitalization was
stable in sensitivity analyses adjusting for time from MI to infarct size
assessment, and for considering HF as the main outcome and death as
a competing risk.
CONCLUSIONS This patient-level analysis of randomized placebo-
controlled trials of multiple therapeutics for STEMI suggests that a
treatment-induced effect on infarct size is related in direction and
quantiﬁable magnitude to a treatment effect on HF hospitalizations.
The data enable the consideration of incorporating infarct size assess-
ment into novel trial analytic approaches as a surrogate endpoint to
assess new therapeutics.
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BACKGROUND No reﬂow phenomenon is not uncommon in patients
with acute ST-segment elevation myocardial infarction (STEMI)
directly revascularized by PCI with immediate stenting (IS). We previ-
ously showed in a pilot study that a minimalist immediate mechanical
intervention (MIMI), based on the use of guidewire or undersized bal-
loons to avoid both large dissection and distal embolization, may be
sufﬁcient to restore ﬂow in emergency in most of patients with acute
STEMI and that recanalization may be sustained by optimized antith-
rombotic regimen allowing to postpone stenting in better conditions.
MIMI also allows to schedule more appropriate medical or surgical
alternative management when more suitable for the patient. We report
in the present study our experience in MIMI approach over 14 years.
METHODS From April 2001 to May 2015, among 2074 primary PCI per-
formed in our institution, 1591were done for a TIMI 0ﬂowof the infarct-
related artery (IRA) at admission coronary angiogram. The choice be-
tween IS and MIMI was done depending on presence of a large
thrombus, complex lesion (bifurcation), indication for urgent or semi-
urgent surgery, questionable signiﬁcant stenosis underlying thrombus.
RESULTS IS was performed in 950 cases. The guidewire or the balloon
failed to cross the lesion in 14 of the 1591patients (0.9%). Among the
remaining 627 cases in whom IS was not performed, once the infarct–
related artery had been recanalized usingMIMI, 483 cases underwent a
two-step strategy. The ﬁnal strategy was medical in 55 cases (10%),
surgery in 170 (35%) and deferred stenting (DS) in 258 (55%) at amean of
4  4 days after initial PCI. IRA reocclusion before ﬁnal strategy
occurred in 1% in all cases with post-MIMI TIMI 3 ﬂow and in 5 of the 17
cases (29%)with post-MIMI TIMI 2ﬂow. The rates of no-reﬂow andTIMI
3 ﬂow after stenting in the DS groupwere 0% and 98.4%, respectively vs
1.8%and91% in the IS group (p<0.001). Distal embolization occurred in
1.8% of the IS and in 0.4% in the DS group (¼0.19). The total rate of TIMI
ﬂow < 3 and distal embolization after stenting was 11% in the IS group
compared to 2% in the DS group (p < 0.0001).
CONCLUSIONS This study suggests that a two-step strategy for the
treatment of acute STEMI by PCI based on a MIMI approach with de-
ferred stenting is possible and seems to achieve better immediate
angiographic results than immediate stenting. However, if a two-step
strategy is applied, a TIMI 3 ﬂow is mandatory after MIMI to avoid
early reocclusion before the ﬁnal strategy.
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BACKGROUND Platelets play a central role in ST-segment elevation
myocardial infarction (STEMI) pathobiology and in the no-reﬂow
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dial injury and subsequent clinical outcomes in STEMI is unclear. We
investigated the effect of platelet count on microvascular obstruction
(MVO), infarct size (IS) and major adverse cardiac events (MACE) in
patients with large anterior STEMI undergoing primary percutaneous
coronary intervention enrolled in the INFUSE-AMI trial.
METHODS Participants from INFUSE-AMI were categorized according to
platelet count tertiles at clinical presentation. Primary endpoints were
cardiac magnetic resonance (MRI) assessed MVO (percentage of left ven-
tricular [LV] mass) at 5 days and IS (% of LV mass) at 30 days. Secondary
endpoint was the rate of major adverse cardiac events (MACE) at 1 year,
deﬁned as the composite of death, reinfarction, new-onset heart failure
(HF) or re-hospitalization for HF. Multivariable regression analysis was
used to evaluate the correlation between PC andMACE at 1 year.
RESULTS Of 447 patients enrolled in the INFUSE-AMI study, 135, 137 and
136weredistributed in the 1st (PC216105/mL), 2nd (PC>216 to266105/mL)
and 3rd tertile (PC >266105/mL), respectively. Patients with lower PC were
older,morecommonlymale,andhad lowerwhitebloodcell countatbaseline.
At 5 days, there were no differences in median MVO across platelet tertiles
(0.3% vs. 0.8% vs. 0.7%; p ¼ 0.86). Similarly, at 30 days there were no dif-
ferences in median IS (17.4% vs. 17.1% vs. 17.7%; p ¼ 0.84). Following multi-
variable adjustment, PC still had no effect on 30-daymyocardial IS (p¼ 0.78).
Finally, while unadjusted analysis demonstrated no difference in 1-year
MACE rates across platelet tertiles (11.3% vs. 10.4% vs. 10.0%; p ¼ 0.81),
following adjustment lower PC was associated with increased risk of 1-year
MACE (per each 100.000/mL decrease; Hazard Ratio¼1.06; 95% CI: 1.01 – 1.12;
p¼ 0.03).
CONCLUSIONS In patients with large anterior STEMI, baseline
platelet count did not have an effect on MVO and infarct size assessed
by MRI. However, lower PC correlated with higher risk of MACE at 1
year. Further studies are required to explore the role of thrombocy-
topenia in the prognosis of patients with STEMI.
CATEGORIES CORONARY: Acute Myocardial Infarction
KEYWORDS Infarct size, Platelet count, ST-segment elevation
myocardial infarction, anterior
TCT-266
Predictors of Mortality in Non-Anterior ST-segment Elevation Myocardial
Infarction: Insights from the Harmonizing Outcomes with Revascularization
and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Gennaro Giustino,1 Joe Dizon,2 Philippe Genereux,3 Roxana Mehran,4
Mario Gössl,5 Bernard J. Gersh,6 Girma M. Ayele,7 Gregg W. Stone8
1Icahn School of Medicine at Mount Sinai, New York City, NY;
2Columbia University, New York, NY; 3Columbia University Medical
Center, New York; 4Icahn School of Medicine at Mount Sinai, New York,
United States; 5Mayo Clinic, Rochester, MN; 6Mayo Clinic College of
Medicine, Rochester, MN; 7Cardiovascular Research Foundation, New
York, NY; 8Columbia University Medical Center and the Cardiovascular
Research Foundation, New York, NY
BACKGROUND Patients with non-anterior ST-segment elevation
myocardial infarction (NA-STEMI) have better prognosis than those
with anterior STEMI (A-STEMI). In contrast to A-STEMI, little is known
regarding factors affecting long-term prognosis in patients with NA-
STEMI. We therefore sought to determine the clinical and angio-
graphic predictors of long-term mortality in patients with NA-STEMI
undergoing primary percutaneous coronary intervention (PPCI).
METHODS Participants from the HORIZONS-AMI trial were catego-
rized according to ECG-deﬁned ST-segment elevation location in NA-
STEMI and A-STEMI. By the ECG core laboratory, NA-STEMI was
deﬁned as ST elevation in the lateral (V5, V6, I, aVL), inferior (II, III,
aVF), infero-lateral (I, II, III, aVF and V5-V6) or antero-lateral (V3 – V6,
I, aVL) ECG leads. Independent predictors of mortality at 3 years were
identiﬁed by Cox proportional hazards modeling including clinical
variables (clinical model), quantitative coronary angiography (QCA)
variables (QCA model), and both (combined model).
RESULTS Among 2,578 patients undergoing PPCI with core laboratory
determined STEMI location, 1,813 (70.3%) had NA-STEMI. Comparedwith
A-STEMI, NA-STEMI patients were younger, more commonly smokers,
and had higher baseline left ventricular ejection fraction (LVEF). In pa-
tientswith NA-STEMI, 84 deaths (4.8%) occurredwithin 3 years of follow-
up. Clinical variables independently associated with 3-year all-cause
mortality in NA-STEMIwere age, Killip Class, peripheral vascular disease,
hemoglobin, platelet count, white blood cell count, symptom-to-balloon
time and heart rate at presentation. In the QCA model, the only variable
independently associated with mortality was baseline LVEF. Signiﬁcant
predictors in the combined model are shown in Table 1.Combined clinical and QCA multivariable model for 3-year mortality in patients with non-anterior STEMI.Independent predictors of 3-year
mortality HR [95% CI] p-valueAge (per year increase) 1.07 [1.04 - 1.10] <0.0001Killip class (per each class
increase)2.03 [1.32 – 3.13] 0.001White blood cell count (per
10.000/mL increase)1.12 [1.03 - 1.21] 0.006Symptom to balloon time (per
30 minutes increase)1.03 [1.02 - 1.04] <0.0001LVEF (per each % decrease) 1.03 [1.00 – 1.06] 0.02LVEF: Left Ventricular Ejection Fraction
CONCLUSIONS In the HORIZONS-AMI trial, patients with NA-STEMI
had a lower clinical risk proﬁle and higher LVEF compared with A-
STEMI. Although generally considered low risk, a combination of
readily available clinical and QCA variables identify NA-STEMI pa-
tients who are at increased risk for mortality after primary PCI.
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BACKGROUND Pre-hospital (PH) ECG enables ﬁeld diagnosis and
triage of STEMI patients to specialized STEMI receiving centers.
Despite the proven beneﬁts of early identiﬁcation, false-positive ECG
interpretations and unnecessary cardiac catheterization laboratory
activations remain a common, challenging problem. We report the
incidence and patterns of agreement between PH and Emergency
Department (ED) ECGs in a large regional STEMI system of care.
METHODS A total of 34 hospitals provide primary PCI as part of a region-
alized STEMI systemof care in Los Angeles County. Each facility is required
to enter data into a county-wide registry of all patientswith possible STEMI
transported by emergency medical services. PH ECG diagnosis of STEMI is
based on software interpretation. ED diagnosis of STEMI is determined by
the receiving physician. Registry data was analyzed for all patients treated
in this system from 2011 to 2014. McNemar’s test was used to assess the
signiﬁcance of the difference between the two correlated proportions.
RESULTS There were 16771 STEMI cases in the registry over four years.
Either the PH or ED ECG was not obtained or not documented in 1358
patients (8%). For cases where both ECG interpretationswere available,
87% (13512/15413) of PH ECG were positive for STEMI, whereas 44%
(6732/15413) of ED ECGwere positive for STEMI (Table 1). Disagreement
occurred in 57% of cases. The most common pattern was discordance
with positive PHECG and negative ED ECG for STEMI. The odds ratio for
discordance was 7.5, 95%CI 7-8, p<0.00001. The high rate of discor-
dance between positive PH and negative ED ECGwas attributed to poor
quality ECG (1770, 23%), dysrhythmia (2032, 26%), mimics such as
pericarditis, hyperkalemia, and Brugada (800, 10%), early repolariza-
tion (188, 2%), vasospasm (5, 0.1%), or undocumented (3026, 39%).
Despite the high frequency of false positive ECGs, a total of 7355 pa-
tients underwent cardiac catheterization. PCI was performed in 5624
and 71 patients received thrombolytic therapy.
CONCLUSIONS Disagreement between PH and ED ECGs is the rule,
not the exception. Reducing false positive PH ECG results will require
improved technology, earlier provider review of PH ECGs and incor-
poration of clinical data into the STEMI activation algorithm.
Table 1. Concordance and Discordance of ECGsED Positive ED Negative TotalPH Positive 5691 7821 13512PH Negative 1041 860 19016732 8681 15413CATEGORIES CORONARY: Acute Myocardial Infarction
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